In this issue:
Elucidating mechanisms of HCV resistance to PIs
Risks of HCC & liver decompensation in HCV-HIV co-infection
Entecavir vs TDF for prognosis of treatment-naïve chronic HBV
HEV burden among patients with haematological malignancies
Lower SVR rates in HCV-infected patients with HCC vs those without
PROs during and after DAAs for chronic HCV
Retreatment with SOF/VEL/VOX for HCV ± HIV
Variants in genotype 3 HCV that reduce response to sofosbuvir
Enhancing rates of HBeAg loss on long-term entecavir in HBV infection
Real-world data on DAA therapies from East Asia
Please login below to download this issue (PDF)